ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …

…, SL Archer, DB Badesch, RJ Barst, HW Farber… - Circulation, 2009 - Am Heart Assoc
Pulmonary hypertension (PH) is a complex, multidisciplinary disorder. Recent advances
have led to increased recognition and new therapies. While some data exist to form …

Pulmonary arterial hypertension

HW Farber, J Loscalzo - New England Journal of Medicine, 2004 - Mass Medical Soc
This review of the mechanism of pulmonary hypertension is focused on pulmonary arterial
hypertension, a disorder that can be idiopathic or can occur in association with other disorders…

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

NP Shah, N Wallis, HW Farber… - American journal of …, 2015 - Wiley Online Library
The prognosis of most leukemia patients treated with BCR‐ABL tyrosine kinase inhibitors (TKIs)
is favorable, and a more precise understanding of serious and potentially irreversible …

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry

…, GE Raskob, CG Elliott, AM Krichman, HW Farber… - Chest, 2010 - Elsevier
… Dr Farber serves as a consultant and is on the speaker's bureau for Actelion. He has
received honoraria for his service on the REVEAL Steering Committee, which is supported by …

Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers

…, GM Garvin, LM Kunches, HW Farber… - … England Journal of …, 1987 - Mass Medical Soc
Gram-negative nosocomial pneumonia may result from retrograde colonization of the pharynx
from the stomach, and this may be more likely when the gastric pH is relatively high. We …

[HTML][HTML] Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk …

RL Benza, M Gomberg-Maitland, CG Elliott, HW Farber… - Chest, 2019 - Elsevier
Background Pulmonary arterial hypertension is a progressive, fatal disease. Published treatment
guidelines recommend treatment escalation on the basis of regular patient assessment …

[HTML][HTML] Five-year outcomes of patients enrolled in the REVEAL Registry

HW Farber, DP Miller, AD Poms, DB Badesch, AE Frost… - Chest, 2015 - Elsevier
BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe disease characterized
by worsening right-sided heart failure, decreasing functional status, and poor survival. …

[HTML][HTML] Endothelial dysfunction in a murine model of mild hyperhomocyst (e) inemia

…, PJ Goldschmidt-Clermont, HW Farber… - The Journal of …, 2000 - Am Soc Clin Investig
Homocysteine is a risk factor for the development of atherosclerosis and its thrombotic
complications. We have employed an animal model to explore the hypothesis that an increase in …

Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings

…, KA STEGER, HW FARBER… - Critical care …, 1992 - journals.lww.com
Objective: To compare nutritional status, gastric colonization, and rates of nosocomial
pneumonia in ICU patients randomized to gastric tube feeding vs. patients fed by an …

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries

…, RJ Barst, RL Benza, CG Elliott, HW Farber… - Chest, 2011 - Elsevier
… Dr Farber serves as a consultant and is on the speaker's bureau for Actelion and has
received honoraria for his service on the REVEAL Steering Committee, which is supported by …